Cost of Revenue Trends: Bio-Techne Corporation vs Corcept Therapeutics Incorporated

Biotech Cost Trends: Bio-Techne vs. Corcept

__timestampBio-Techne CorporationCorcept Therapeutics Incorporated
Wednesday, January 1, 2014106352000882000
Thursday, January 1, 20151449690001361000
Friday, January 1, 20161623640002058000
Sunday, January 1, 20171884620003554000
Monday, January 1, 20182108500005215000
Tuesday, January 1, 20192405150005504000
Wednesday, January 1, 20202554970005582000
Friday, January 1, 20212981820005281000
Saturday, January 1, 20223491030005385000
Sunday, January 1, 20233668870006481000
Monday, January 1, 2024389335000
Loading chart...

Cracking the code

Cost of Revenue Trends in the Biotech Sector

In the ever-evolving biotech industry, understanding cost dynamics is crucial for investors and stakeholders. Bio-Techne Corporation and Corcept Therapeutics Incorporated, two prominent players, showcase intriguing trends in their cost of revenue from 2014 to 2023. Bio-Techne's cost of revenue has surged by approximately 266%, reflecting its aggressive growth strategy and expanding operations. In contrast, Corcept Therapeutics has experienced a more modest increase of around 635%, indicating a steady yet significant scaling of its operations.

Bio-Techne's cost of revenue peaked in 2023, reaching nearly 367 million, while Corcept's costs rose to about 6.5 million in the same year. Notably, data for 2024 is incomplete, highlighting the need for continuous monitoring. These trends underscore the diverse strategies within the biotech sector, where companies balance growth with cost management to maintain competitive advantage.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025